06.15.21

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Trial of CLS-AX for the Treatment of Wet AMD

Source: Clearside Biomedical

03.02.21

Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMD

Source: Clearside Biomedical

02.16.21

Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

Source: Clearside Biomedical

01.12.21

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMD

Source: Clearside Biomedical

11.16.20

Clearside Biomedical Announces Data Presentations at the AAO 2020

Source: Clearside Biomedical

08.10.20

Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Space

Source: Clearside Biomedical

06.17.20

Clearside Biomedical Announces Numerous Presentations at ARVO 2020

Source: Clearside Biomedical

View more stories